MM Asset Management, Inc. recently announced the acquisition of new stake in Better Therapeutics Inc (NASDAQ:BTTX). This fresh investment now brings its stake to 3.34% valued currently at $0.31 million. In addition, The Vanguard Group, Inc. raised its holdings by 61418.0 to 0.5 million shares. And SSgA Funds Management, Inc. has lifted its position by 29.65% or 13400.0 shares – to 58600.0 shares.
With over 7.23 million Better Therapeutics Inc (BTTX) shares trading Monday and a closing price of $0.20 on the day, the dollar volume was approximately $1.45 million. The shares have shown a negative half year performance of -78.06% and its price on 01/08/24 gained nearly 16.24%. Currently, there are 49.86M common shares owned by the public and among those 24.34M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 15 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 8,493,819 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Better Therapeutics Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.33 million shares of the company’s stock, all valued at over $63904.0. Fidelity Extended Market Index Fu now owns shares totaling to 0.18% of the shares outstanding.
However, the script later moved the day high at 0.2050, up 16.24%. The company’s stock has a 5-day price change of 1.28% and -41.91% over the past three months. BTTX shares are trading 1.28% year to date (YTD), with the 12-month market performance down to -83.26% lower. It has a 12-month low price of $0.14 and touched a high of $1.61 over the same period. BTTX has an average intraday trading volume of 2.37 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.26%, 4.91%, and -67.92% respectively.
Institutional ownership of Better Therapeutics Inc (NASDAQ: BTTX) shares accounts for 5.04% of the company’s 49.86M shares outstanding. Mutual fund holders own 3.83%, while other institutional holders and individual stakeholders account for 48.38% and 1.47% respectively.
It has a market capitalization of $9.85M and a beta (3y monthly) value of 2.46. The earnings-per-share (ttm) stands at -$1.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.45% over the week and 15.80% over the month.
Analysts forecast that Better Therapeutics Inc (BTTX) will achieve an EPS of -$0.12 for the current quarter, -$0.17 for the next quarter and -$1 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.12 while analysts give the company a high EPS estimate of -$0.12. Comparatively, EPS for the current quarter was -$0.37 a year ago. Earnings per share for the fiscal year are expected to increase by 50.59%, and 6.59% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Better Therapeutics Inc (BTTX) as a “Strong Buy” at a consensus score of 1.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BTTX, a number of firms have released research notes about the stock. Chardan Capital Markets stated their Buy rating for the stock in a research note on November 24, 2021, with the firm’s price target at $17.
